-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
In recent years, with the continuous introduction of policies to encourage innovation, such as the accelerated review of new drugs and the normalization of medical insurance negotiations, pharmaceutical companies are enthusiastic about innovation.
At the same time, centralized procurement and medical insurance payment have forced traditional pharmaceutical companies to reform.
In other words, companies with outstanding R&D capabilities and abundant reserves have more advantages
.
In November 2021, CDE's new policy "Guidelines for Clinical Research and Development of Antitumor Drugs Oriented to Clinical Values" is regarded by the industry as a signal to combat "pseudo-innovation"
.
However, judging from the momentum of pharmaceutical companies in the first few months of 2022, the enthusiasm for new drug research and development has not diminished, and cooperation has become a trend for many companies to develop together
.
For example, on April 28, Kain Technology announced that it signed a strategic agreement with Saifu Pharmaceutical, a one-stop CRO service provider for innovative drugs.
The two parties will establish a long-term and strategic business partnership to promote the common development of innovative R&D business
.
It is reported that Kain Technology is a biopharmaceutical company that uses biotechnology as a platform, focuses on the field of viruses and immune diseases, and is committed to providing prevention and treatment solutions
.
Also in April, Nhua Pharmaceutical, a leading domestic central nervous system drug company, and Shenshi Technology reached a strategic cooperation agreement
.
The agreement stipulates that the two parties will fully combine the deep drug development experience of NHU in the field of central nervous system, and the efficient and accurate computing advantages of the Hermite drug design platform of Shenshi Technology, to jointly promote the development of small-molecule innovative drugs of NHU in the field of CNS.
R&D work
.
At the same time, the two parties will further explore the advantages of cooperation, combine AI technology and innovative molecular research and development more widely, and accelerate and expand the research and development process and innovation dimension of drugs in the central nervous system
.
On March 24, Ruige Medicine and NVIDIA announced a strategic cooperation
.
According to the agreement, Ruige Medicine has become an in-depth partner of NVIDIA Inception in the field of innovative drugs in China
.
Ruige Medicine will work closely with NVIDIA to integrate high-performance computing technology into Ruige's self-developed rCARD platform to accelerate the source discovery and research and development of innovative drugs
.
The industry said that the strong strategic cooperation can more effectively ensure the rapid advancement of the precise research and development of new drugs, improve the efficiency of new drug research and development for pharmaceutical companies, and save costs
.
Judging from the partners sought by pharmaceutical companies this year, artificial intelligence companies have become partners for many pharmaceutical companies to seek cooperation
.
At present, the biomedical industry with the integration of artificial intelligence technology has entered a new stage of development, with both opportunities and challenges
.
It is understood that the traditional biopharmaceutical industry uses a high-throughput screening method to screen target compounds, which requires a lot of manpower, time and trial and error costs
.
In the era of big data, artificial intelligence platforms can not only efficiently find new drug targets, design and synthesize biologically active molecules, but also greatly reduce R&D costs and improve the overall efficiency and success rate of innovative drug R&D
.
However, the industry also reminds that no AI pharmaceutical products have been officially launched at present, and many pharmaceutical companies will find problems such as lack of relevant professionals in the process of layout, which requires further exploration by industry companies
.
It is reported that a pharmaceutical person said that the company attaches great importance to the application and potential of new technologies in the field of innovative drug research and development
.
To this end, the company has also established an interdisciplinary team of scientists to accelerate the integration of multi-disciplinary technologies such as big data, artificial intelligence, high-performance computing and innovative drug development.
new chapter
.
At the same time, centralized procurement and medical insurance payment have forced traditional pharmaceutical companies to reform.
In other words, companies with outstanding R&D capabilities and abundant reserves have more advantages
.
In November 2021, CDE's new policy "Guidelines for Clinical Research and Development of Antitumor Drugs Oriented to Clinical Values" is regarded by the industry as a signal to combat "pseudo-innovation"
.
However, judging from the momentum of pharmaceutical companies in the first few months of 2022, the enthusiasm for new drug research and development has not diminished, and cooperation has become a trend for many companies to develop together
.
For example, on April 28, Kain Technology announced that it signed a strategic agreement with Saifu Pharmaceutical, a one-stop CRO service provider for innovative drugs.
The two parties will establish a long-term and strategic business partnership to promote the common development of innovative R&D business
.
It is reported that Kain Technology is a biopharmaceutical company that uses biotechnology as a platform, focuses on the field of viruses and immune diseases, and is committed to providing prevention and treatment solutions
.
Also in April, Nhua Pharmaceutical, a leading domestic central nervous system drug company, and Shenshi Technology reached a strategic cooperation agreement
.
The agreement stipulates that the two parties will fully combine the deep drug development experience of NHU in the field of central nervous system, and the efficient and accurate computing advantages of the Hermite drug design platform of Shenshi Technology, to jointly promote the development of small-molecule innovative drugs of NHU in the field of CNS.
R&D work
.
At the same time, the two parties will further explore the advantages of cooperation, combine AI technology and innovative molecular research and development more widely, and accelerate and expand the research and development process and innovation dimension of drugs in the central nervous system
.
On March 24, Ruige Medicine and NVIDIA announced a strategic cooperation
.
According to the agreement, Ruige Medicine has become an in-depth partner of NVIDIA Inception in the field of innovative drugs in China
.
Ruige Medicine will work closely with NVIDIA to integrate high-performance computing technology into Ruige's self-developed rCARD platform to accelerate the source discovery and research and development of innovative drugs
.
The industry said that the strong strategic cooperation can more effectively ensure the rapid advancement of the precise research and development of new drugs, improve the efficiency of new drug research and development for pharmaceutical companies, and save costs
.
Judging from the partners sought by pharmaceutical companies this year, artificial intelligence companies have become partners for many pharmaceutical companies to seek cooperation
.
At present, the biomedical industry with the integration of artificial intelligence technology has entered a new stage of development, with both opportunities and challenges
.
It is understood that the traditional biopharmaceutical industry uses a high-throughput screening method to screen target compounds, which requires a lot of manpower, time and trial and error costs
.
In the era of big data, artificial intelligence platforms can not only efficiently find new drug targets, design and synthesize biologically active molecules, but also greatly reduce R&D costs and improve the overall efficiency and success rate of innovative drug R&D
.
However, the industry also reminds that no AI pharmaceutical products have been officially launched at present, and many pharmaceutical companies will find problems such as lack of relevant professionals in the process of layout, which requires further exploration by industry companies
.
It is reported that a pharmaceutical person said that the company attaches great importance to the application and potential of new technologies in the field of innovative drug research and development
.
To this end, the company has also established an interdisciplinary team of scientists to accelerate the integration of multi-disciplinary technologies such as big data, artificial intelligence, high-performance computing and innovative drug development.
new chapter
.
